CRISPR Therapeutics CEO Samarth Kulkarni said: “As we advance our allogeneic CAR-T programs into the clinic, we are preparing for the future by securing our access to the
The post CRISPR, MaxCyte expand partnership to develop immuno-oncology therapies appeared first on Pharma Business review.
Original Article: CRISPR, MaxCyte expand partnership to develop immuno-oncology therapies